“The current condition has uncovered some structural weaknesses inside the EU’s medicines offer chain and also a significant dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides reported. She recommended that offer chain concerns be resolved in an EU pharmaceutical system predicted for being introduced by the top